Overview

Durvalumab Treatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Toxicity

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects being treated with durvalumab has on cancer. The researchers doing this study also want to evaluate if prednisone (a type of steroid), when given together with durvalumab, can reduce any side effects.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborator:
AstraZeneca
Treatments:
Antibodies, Monoclonal
Durvalumab
Prednisone